Sara Galimberti

List of Publications by Year
in descending order

346 papers	6,239 citations	87888 38 h-index	114465 63 g-index
351 all docs	351 docs citations	351 times ranked	8805 citing authors

#	Article	IF	Citations
1	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematology,the, 2020, 7, e737-e745.	4.6	430
2	The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Annals of Oncology, 2013, 24, 454-462.	1.2	232
3	R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology, 2013, 31, 1506-1513.	1.6	223
4	Unexpected cardiotoxicity in haematological bortezomib treated patients. British Journal of Haematology, 2007, 138, 396-397.	2.5	181
5	Suspension of Bone Marrowâ€"Derived Undifferentiated Mesenchymal Stromal Cells for Repair of Superficial Digital Flexor Tendon in Race Horses. Tissue Engineering, 2007, 13, 2949-2955.	4.6	179
6	Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. British Journal of Haematology, 2012, 156, 346-353.	2.5	122
7	Foods, nutrients and the risk of oral and pharyngeal cancer. British Journal of Cancer, 2013, 109, 2904-2910.	6.4	95
8	Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. Clinical Cancer Research, 2014, 20, 6398-6405.	7.0	94
9	Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. Journal of Clinical Oncology, 2016, 34, 1175-1181.	1.6	94
10	Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab. Bone Marrow Transplantation, 2003, 32, 57-63.	2.4	88
11	Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. Frontiers in Oncology, 2018, 8, 194.	2.8	84
12	BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia. Frontiers in Oncology, 2019, 9, 939.	2.8	83
13	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood, 2013, 122, 3759-3766.	1.4	82
14	Safety and efficacy of bortezomibâ€based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. European Journal of Haematology, 2010, 84, 223-228.	2.2	77
15	Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. Annals of Hematology, 2008, 87, 405-412.	1.8	76
16	Differences among young adults, adults and elderly chronic myeloid leukemia patients. Annals of Oncology, 2015, 26, 185-192.	1.2	72
17	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. Blood Advances, 2019, 3, 4280-4290.	5.2	66
18	Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment. Stem Cells Translational Medicine, 2018, 7, 305-314.	3.3	65

#	Article	IF	Citations
19	Effectsof Aspergillus fumigatusgliotoxin and methylprednisolone on human neutrophils: implications for the pathogenesis of invasive aspergillosis. Journal of Leukocyte Biology, 2007, 82, 839-848.	3.3	61
20	Highly sensitive MYD88 ^{L265P} mutation detection by droplet digital polymerase chain reaction in WaldenstrÃ¶m macroglobulinemia. Haematologica, 2018, 103, 1029-1037.	3.5	61
21	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood, 2020, 135, 534-541.	1.4	61
22	The JAKâ€“STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. European Heart Journal, 2021, 42, 4389-4400.	2.2	61
23	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica, 2019, 104, 1589-1596.	3.5	58
24	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. Leukemia, 2020, 34, 2260-2261.	7.2	57
25	Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leukemia Research, 2005, 29, 961-966.	0.8	56
26	Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer Journal, 2013, 3, e162-e162.	6.2	56
27	COVIDâ€19 elicits an impaired antibody response against SARSâ€CoVâ€2 in patients with haematological malignancies. British Journal of Haematology, 2021, 195, 371-377.	2.5	56
28	The value of repeat biopsy in the management of lupus nephritis: an international multicentre study in a large cohort of patients. Nephrology Dialysis Transplantation, 2013, 28, 3014-3023.	0.7	55
29	New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions. Frontiers in Immunology, 2020, 11, 578314.	4.8	55
30	Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the realâ€life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematological Oncology, 2019, 37, 296-302.	1.7	53
31	Rituximab as treatment for minimal residual disease in hairy cell leukaemia. European Journal of Haematology, 2004, 73, 412-417.	2.2	51
32	Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. Experimental Hematology, 2015, 43, 1015-1018.e1.	0.4	51
33	Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leukemia Research, 2004, 28, 367-372.	0.8	46
34	ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1419-1432.	3.3	46
35	MDR1 polymorphism influences the outcome of multiple myeloma patients. British Journal of Haematology, 2007, 137, 454-456.	2.5	45
36	The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenomics Journal, 2014, 14, 328-335.	2.0	45

#	Article	IF	Citations
37	Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. Journal of Hematology and Oncology, 2019, 12, 131.	17.0	45
38	Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2. International Journal of Molecular Sciences, 2020, 21, 3622.	4.1	45
39	Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment. Cancer Genetics and Cytogenetics, 2005, 162, 57-62.	1.0	38
40	Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Haematologica, 2016, 101, e66-e68.	3.5	36
41	High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naÃ¯ve lymphocytes and prevents TTV reactivation. Leukemia Research, 2018, 70, 20-24.	0.8	36
42	Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2. Frontiers in Oncology, 2020, 10, 1428.	2.8	36
43	The CoV-2 outbreak: how hematologists could help to fight Covid-19. Pharmacological Research, 2020, 157, 104866.	7.1	36
44	Human autologous plasmaâ€derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. Journal of Orthopaedic Research, 2008, 26, 176-183.	2.3	34
45	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. Journal of Clinical Oncology, 2022, 40, 729-739.	1.6	34
46	Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia. International Journal of Molecular Sciences, 2015, 16, 22811-22829.	4.1	33
47	Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Annals of Oncology, 2010, 21, 851-854.	1.2	32
48	ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology. Oncotarget, 2017, 8, 4914-4921.	1.8	32
49	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. Annals of Hematology, 2018, 97, 95-100.	1.8	32
50	Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended followâ€up. British Journal of Haematology, 2008, 143, 296-298.	2.5	31
51	Safety and efficacy of ⁹⁰<scp>Y</scp>ttriumâ€<scp>I</scp>britumomabâ€<scp>T</scp>iuxetan for untreated follicular lymphoma patients. An <scp>I</scp>talian cooperative study. British Journal of Haematology, 2014, 164, 710-716.	2.5	31
52	MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenetics and Genomics, 2008, 18, 383-389.	1.5	30
53	Realâ€Time <scp>PCR</scp> and Droplet Digital <scp>PCR</scp>: two techniques for detection of the <scp>JAK</scp>2^{V617F} mutation in Philadelphiaâ€negative chronic myeloproliferative neoplasms. International Journal of Laboratory Hematology, 2015, 37, 766-773.	1.3	30
54	An advantageous method to evaluate IgH rearrangement and its role in minimal residual disease detection. Leukemia Research, 1999, 23, 921-929.	0.8	29

#	Article	IF	Citations
55	Characterization of Ph-negative abnormal clones emerging during imatinib therapy. Cancer, 2007, 109, 2466-2472.	4.1	29
56	Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. Leukemia and Lymphoma, 2013, 54, 2458-2465.	1.3	29
57	Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. Lancet Oncology, The, 2006, 7, 350-352.	10.7	28
58	2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leukemia Research, 2010, 34, 184-189.	0.8	28
59	Flow Cytometry Assessment of CD26 + Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia. Cytometry Part B - Clinical Cytometry, 2019, 96, 294-299.	1.5	28
60	CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer Journal, 2020, 10, 96.	6.2	28
61	A prognostic model for patients with lymphoma and COVID-19: aÂmulticentre cohort study. Blood Advances, 2022, 6, 327-338.	5.2	28
62	Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. British Journal of Haematology, 2003, 120, 405-412.	2.5	27
63	The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice. Frontiers in Oncology, 2019, 9, 528.	2.8	27
64	The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia. Frontiers in Pharmacology, 2016, 7, 363.	3.5	26
65	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with secondâ€generation tyrosine kinase inhibitors in the realâ€life practice: Identification of risk factors and the role of prophylaxis. American Journal of Hematology, 2018, 93, E159-E161.	4.1	26
66	Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. Oncotarget, 2016, 7, 72311-72321.	1.8	26
67	Changes in RPS14 expression levels during lenalidomide treatment in Lowâ€and Intermediateâ€1â€risk myelodysplastic syndromes with chromosome 5q deletion. European Journal of Haematology, 2010, 85, 231-235.	2.2	25
68	Torquetenovirus (TTV) load is associated with mortality in Italian elderly subjects. Experimental Gerontology, 2018, 112, 103-111.	2.8	25
69	Gelatin/PLLA Spongeâ€Like Scaffolds Allow Proliferation and Osteogenic Differentiation of Human Mesenchymal Stromal Cells. Macromolecular Bioscience, 2008, 8, 819-826.	4.1	24
70	Hyperbaric oxygen therapy in BKV-associated hemorrhagic cystitis refractory to intravenous and intravesical cidofovir: Case report and review of literature. Leukemia Research, 2009, 33, 556-560.	0.8	24
71	Frontline Dasatinib Treatment in a â€œReal-Lifeâ€•Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. Neoplasia, 2016, 18, 536-540.	5.3	24
72	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget, 2016, 7, 80083-80090.	1.8	24

#	Article	IF	Citations
73	Low dose 2-CdA schedule activity in splenic marginal zone lymphomas. Hematological Oncology, 2003, 21, 163-168.	1.7	23
74	Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gammaâ€“delta T cells. European Journal of Clinical Investigation, 2009, 39, 813-818.	3.4	23
75	WT1 expression levels at diagnosis could predict longâ€term timeâ€toâ€progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes. British Journal of Haematology, 2010, 149, 451-454.	2.5	23
76	Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. Annals of Hematology, 2013, 92, 25-32.	1.8	23
77	Panobinostat for the treatment of acute myelogenous leukemia. Expert Opinion on Investigational Drugs, 2016, 25, 1117-1131.	4.1	23
78	Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?. Journal of Clinical Medicine, 2020, 9, 3865.	2.4	23
79	False positive PET scanning caused by inactivated influenza virus vaccination during complete remission from anaplastic T-cell lymphoma. Annals of Hematology, 2008, 87, 343-344.	1.8	22
80	Correspondence between salivary proteomic pattern and clinical course in primary SjÃ¶gren syndrome and non-Hodgkin's lymphoma: a case report. Journal of Translational Medicine, 2011, 9, 188.	4.4	22
81	Polycomb genes are associated with response to imatinib in chronic myeloid leukemia. Epigenomics, 2015, 7, 757-765.	2.1	22
82	Good manufacturing practiceâ€“grade fibrin gel is useful as a scaffold for human mesenchymal stromal cells and supports in vitro osteogenic differentiation. Transfusion, 2008, 48, 2246-2251.	1.6	21
83	Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genetics and Cytogenetics, 2010, 199, 110-120.	1.0	21
84	Prospective qualitative and quantitative non-invasive evaluation of intestinal acute GVHD by contrast-enhanced ultrasound sonography. Bone Marrow Transplantation, 2013, 48, 1421-1428.	2.4	21
85	Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. International Journal of Cardiology, 2020, 301, 163-166.	1.7	21
86	Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome. Cancers, 2021, 13, 1311.	3.7	21
87	Impaired function of gamma-delta lymphocytes in melanoma patients. European Journal of Clinical Investigation, 2011, 41, 1186-1194.	3.4	20
88	Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients. Cancers, 2020, 12, 1738.	3.7	20
89	COVIDâ€19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. British Journal of Haematology, 2022, 196, 559-565.	2.5	20
90	RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.. Hematological Oncology, 2019, 37, 153-154.	1.7	19

#	Article	IF	Citations
91	Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. International Journal of Cardiology, 2019, 288, 124-127.	1.7	19
92	Multidrug resistance related genes and p53 expression in human non small cell lung cancer. Anticancer Research, 1998, 18, 2973-6.	1.1	19
93	Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients. Journal of Hematology and Oncology, 2016, 9, 63.	17.0	18
94	The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. Annals of Hematology, 2016, 95, 211-219.	1.8	18
95	The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia. Frontiers in Oncology, 2018, 8, 555.	2.8	18
96	Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia. Bone Marrow Transplantation, 1999, 24, 345-348.	2.4	17
97	Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice. Leukemia Research, 2002, 26, 19-27.	0.8	17
98	Carboxyâ€terminal fragment of osteogenic growth peptide regulates myeloid differentiation through RhoA. Journal of Cellular Biochemistry, 2004, 93, 1231-1241.	2.6	17
99	The Efficacy of Rituximab plus Hyper-CVAD Regimen in Mantle Cell Lymphoma Is Independent of FCÎ³RIIIa and FCÎ³RIIa Polymorphisms. Journal of Chemotherapy, 2007, 19, 315-321.	1.5	17
100	Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib. Leukemia Research, 2010, 34, 1336-1339.	0.8	17
101	Vascular Endothelial Growth Factor Polymorphisms in Mantle Cell Lymphoma. Acta Haematologica, 2010, 123, 91-95.	1.4	17
102	Significant efficacy of 2-chlorodeoxyadenosineÂ± rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up. Annals of Oncology, 2013, 24, 2434-2438.	1.2	17
103	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. Annals of Hematology, 2019, 98, 2329-2338.	1.8	17
104	Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches. Frontiers in Oncology, 2019, 9, 833.	2.8	17
105	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy. Cancers, 2021, 13, 291.	3.7	17
106	The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose. Biomedicines, 2021, 9, 1480.	3.2	17
107	The Clinical Relevance of the Expression of Several Multidrug-Resistant-Related Genes in Patients with Primary Acute Myeloid Leukemia. Journal of Chemotherapy, 2003, 15, 374-379.	1.5	16
108	Actin polymerization in neutrophils from donors of peripheral blood stem cells: Divergent effects of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factor. American Journal of Hematology, 2006, 81, 318-323.	4.1	16

#	Article	IF	Citations
109	Recovering from chronic myeloid leukemia: the patientsâ€™ perspective seen through the lens of narrative medicine. Quality of Life Research, 2017, 26, 2739-2754.	3.1	16
110	Cell clonality in hypereosinophilic syndrome: what pathogenetic role?. Clinical and Experimental Rheumatology, 2007, 25, 17-22.	0.8	16
111	Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis. European Journal of Haematology, 2004, 72, 45-51.	2.2	15
112	Evaluation of theMDR1,ABCG2,Topoisomerases IIÎ±andGSTÏ€gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. Leukemia and Lymphoma, 2007, 48, 1502-1509.	1.3	15
113	Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk. Leukemia Research, 2008, 32, 988-990.	0.8	15
114	COVID-19: the new challenge for rheumatologists. First update. Clinical and Experimental Rheumatology, 2020, 38, 373-382.	0.8	15
115	Glycosylated or non-glycosylated G-CSF differently influence human granulocyte functions through RhoA. Leukemia Research, 2005, 29, 1285-1292.	0.8	14
116	Different Î³/Î´ T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation. Leukemia Research, 2006, 30, 529-535.	0.8	14
117	PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells. Leukemia Research, 2008, 32, 103-112.	0.8	14
118	The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia. Frontiers in Oncology, 2019, 9, 532.	2.8	14
119	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. Annals of Hematology, 2021, 100, 2005-2014.	1.8	14
120	The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. Oncotarget, 2017, 8, 88021-88033.	1.8	14
121	Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool. Diagnostics, 2022, 12, 1305.	2.6	14
122	Could age modify the effect of genetic variants in IL6 and TNF-Î± genes in multiple myeloma?. Leukemia Research, 2012, 36, 594-597.	0.8	13
123	Minimal residual disease (MRD) in nonâ€Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network. Hematological Oncology, 2019, 37, 368-374.	1.7	13
124	Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Leukemia Research, 2002, 26, 839-848.	0.8	12
125	Carboxy-terminal fragment of osteogenic growth peptide in vitro increases bone marrow cell density in idiopathic myelofibrosis. British Journal of Haematology, 2003, 121, 76-85.	2.5	12
126	Microwave ablation of hepatic tumors with a third generation system: locoâ€‘regional efficacy in a prospective cohort study with intermediate term follow-up. Zeitschrift Fur Gastroenterologie, 2016, 54, 541-547.	0.5	12

#	Article	IF	Citations
127	Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2017, 79, 767-773.	2.3	12
128	HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia. Leukemia Research, 2017, 61, 1-5.	0.8	12
129	How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases. Journal of Chemotherapy, 2017, 29, 126-129.	1.5	12
130	Precision Medicine in Lymphoma by Innovative Instrumental Platforms. Frontiers in Oncology, 2019, 9, 1417.	2.8	12
131	Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice. Pharmacological Research, 2021, 167, 105537.	7.1	12
132	Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines. Leukemia, 2008, 22, 628-631.	7.2	11
133	VDTPACEÂAs Salvage Therapy For Heavily Pretreated MM Patients. Blood, 2013, 122, 5377-5377.	1.4	11
134	Contemporaneous appearance, 18 years after allogeneic bone marrow transplantation, of myelodysplastic syndrome in the patient and the donor. Bone Marrow Transplantation, 2004, 33, 859-861.	2.4	10
135	NQO1*2 polymorphism and response to treatment in patients with multiple myeloma. Leukemia Research, 2007, 31, 1029-1030.	0.8	10
136	Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation. Leukemia, 2007, 21, 176-178.	7.2	10
137	MDR1 C3435T Polymorphism Indicates a Different Outcome in Advanced Multiple Myeloma. Acta Haematologica, 2009, 122, 42-45.	1.4	10
138	Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma. Cancer Management and Research, 2010, 2, 181.	1.9	10
139	Comparison of two realâ€time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and realâ€time quantitative polymerase chain reaction performance. Hematological Oncology, 2014, 32, 133-138.	1.7	10
140	Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. Annals of Hematology, 2019, 98, 1885-1890.	1.8	10
141	TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors. Expert Opinion on Investigational Drugs, 2020, 29, 869-880.	4.1	10
142	Assessment of the 4â€factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. American Journal of Hematology, 2021, 96, E168-E171.	4.1	10
143	Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib. Frontiers in Oncology, 2021, 11, 672287.	2.8	10
144	Assessment of droplet digital polymerase chain reaction for measuring BCRâ€ABL1 in chronic myeloid leukaemia in an international interlaboratory study. British Journal of Haematology, 2021, 194, 53-60.	2.5	10

#	Article	IF	Citations
145	Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes. Blood, 2018, 132, 43-43.	1.4	10
146	Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi realâ€life experience. Hematological Oncology, 2022, 40, 32-40.	1.7	10
147	High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases. Clinical and Experimental Rheumatology, 2005, 23, 877-80.	0.8	10
148	Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study. Frontiers in Oncology, 2022, 12, 839915.	2.8	10
149	Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer. Journal of Clinical Medicine, 2022, 11, 1801.	2.4	10
150	Activation of the zinc-sensing receptor GPR39 promotes T-cell reconstitution after hematopoietic cell transplant in mice. Blood, 2022, 139, 3655-3666.	1.4	10
151	Dose-dependent induction of apoptosis by R-apomorphine in CHO-K1 cell line in culture. Neuropharmacology, 2003, 45, 182-189.	4.1	9
152	PEG-Filgrastim activity on granulocyte functions. Leukemia Research, 2007, 31, 1453-1455.	0.8	9
153	Poor prognosis chronic myeloid leukemia with a complex variant Philadelphia translocation, t(9;10;22)(q34;q24;q11). Leukemia Research, 2007, 31, 1765-1766.	0.8	9
154	Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia. Leukemia Research, 2008, 32, 191-192.	0.8	9
155	Phenobarbital-Associated Bone Marrow Aplasia: A Case Report and Review of the Literature. Acta Haematologica, 2008, 119, 18-21.	1.4	9
156	Contrast-enhanced ultrasonography in nodular splenomegaly associated with type B Niemannâ€“Pick disease: an atypical hemangioma enhancement pattern. Journal of Ultrasound, 2009, 12, 85-92.	1.3	9
157	Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. Journal of Hematology and Oncology, 2012, 5, 53.	17.0	9
158	Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis. Supportive Care in Cancer, 2016, 24, 4487-4493.	2.2	9
159	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. Annals of Hematology, 2020, 99, 1525-1530.	1.8	9
160	GTF2I Mutations Are Common in Thymic Epithelial Tumors But Not in Hematological Malignancies. , 2017, 37, 5459-5462.		9
161	The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma. Bone Marrow Transplantation, 2002, 29, 581-587.	2.4	8
162	Granulocytic sarcoma and subsequent acute leukemia recurrence with different biologic characteristics 5 years after allogeneic bone marrow transplantation for acute myeloid leukemia. Bone Marrow Transplantation, 2006, 37, 897-898.	2.4	8

#	Article	IF	Citations
163	Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms. Leukemia Research, 2008, 32, 49-53.	0.8	8
164	Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome. British Journal of Haematology, 2018, 181, 267-270.	2.5	8
165	Interference of Monoclonal Gammopathy with Fibrinogen Assay Producing Spurious Dysfibrinogenemia. TH Open, 2019, 03, e64-e66.	1.4	8
166	BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS. Leukemia, 2021, 35, 2102-2107.	7.2	8
167	Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results. Frontiers in Immunology, 2020, 11, 573156.	4.8	8
168	Bosutinib in the realâ€life treatment of chronic myeloid leukemia patients aged >65Âyears resistant/intolerant to previous tyrosineâ€kinase inhibitors. Hematological Oncology, 2021, 39, 401-408.	1.7	8
169	<scp>TP53</scp> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. American Journal of Hematology, 2021, 96, E306-E310.	4.1	8
170	Ficollâ€hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis. International Journal of Laboratory Hematology, 2018, 40, 201-208.	1.3	8
171	Myeloid neoplasms and autoimmune diseases: markers of association. Clinical and Experimental Rheumatology, 2022, 40, 49-55.	0.8	8
172	Imatinib therapy in Hypereosinophilic Syndrome: A case of molecular remission. Leukemia Research, 2005, 29, 1097-1098.	0.8	7
173	Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting. Transplant Immunology, 2005, 15, 173-177.	1.2	7
174	Two Cases of Plasma Cell Leukemia with Atypical Immunophenotype. Acta Haematologica, 2007, 118, 27-29.	1.4	7
175	Unusual association of endometrial cancer and multiple myeloma. Gynecologic Oncology, 2008, 110, 265-266.	1.4	7
176	Plateletâ€derived growth factor beta receptor (PDGFRB) gene is rearranged in a significant percentage of myelodysplastic syndromes with normal karyotype. British Journal of Haematology, 2009, 147, 763-766.	2.5	7
177	Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: A report in a case of delayed graft failure. Leukemia Research, 2009, 33, 178-181.	0.8	7
178	Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Doxorubicin and Dexamethasone as Induction Therapy in Previously Untreated Multiple Myeloma Patients. Acta Haematologica, 2013, 129, 35-39.	1.4	7
179	Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors. Blood, 2019, 134, 1649-1649.	1.4	7
180	From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox. Frontiers in Oncology, 2021, 11, 752192.	2.8	7

#	Article	IF	Citations
181	Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: Difficulties at diagnosis and rational of the therapeutic strategy. Leukemia Research, 2006, 30, 349-353.	0.8	6
182	Acute myeloid leukaemia after treatment with ⁹⁰Yâ€ibritumomab tiuxetan for follicular lymphoma. Hematological Oncology, 2008, 26, 179-181.	1.7	6
183	Complex translocation t(6;9;22)(p21.1;q34;q11) at diagnosis is a therapy resistance index in chronic myeloid leukaemia. Leukemia Research, 2008, 32, 190-191.	0.8	6
184	Conditioning response to granulocyte colony-stimulating factor via the dipeptidyl peptidase IV-adenosine deaminase complex. Journal of Leukocyte Biology, 2008, 84, 331-337.	3.3	6
185	Fatal ongoing human cytomegalovirus reactivation during highâ€dose melphalan and autologous stem cell transplantation. Journal of Medical Virology, 2009, 81, 857-860.	5.0	6
186	Highâ€dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: A retrospective investigation on 133 patients treated in a single institution. American Journal of Hematology, 2011, 86, 762-767.	4.1	6
187	Increased values of the circulating PDGFÎ² sustains the â€œwithdrawal syndromeâ€•after tyrosine kinase inhibitor discontinuation in patients affected by chronic myeloid leukemia. Blood Cells, Molecules, and Diseases, 2015, 55, 211-212.	1.4	6
188	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. Haematologica, 2015, 100, 517-524.	3.5	6
189	Chronic Myeloid Leukemia Patientâ€™s Voice About the Experience of Treatment-Free Remission Failure: Results From the Italian Sub-Study of ENESTPath Exploring the Emotional Experience of Patients During Different Phases of a Clinical Trial. Frontiers in Psychology, 2019, 10, 329.	2.1	6
190	In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. Leukemia, 2020, 34, 929-931.	7.2	6
191	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. Blood Cancer Journal, 2020, 10, 66.	6.2	6
192	Early Diagnosis of Neutropenic Enterocolitis by Bedside Ultrasound in Hematological Malignancies: A Prospective Study. Journal of Clinical Medicine, 2021, 10, 4277.	2.4	6
193	EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy. Blood, 2019, 134, 124-124.	1.4	6
194	Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status?. Blood, 2013, 122, 1482-1482.	1.4	6
195	Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). Frontiers in Oncology, 2022, 12, 835563.	2.8	6
196	ITF2357 interferes with apoptosis and inflammatory pathways in the HL-60 model: a gene expression study. Anticancer Research, 2010, 30, 4525-35.	1.1	6
197	Role of Low-Dose 2-CdA in Refractory or Resistant Lymphoplasmocytic Lymphoma. Journal of Chemotherapy, 2004, 16, 388-391.	1.5	5
198	Adjunctive chromosomal abnormalities in Philadelphia-negative cells of CML patients treated with Imatinib. European Journal of Clinical Investigation, 2004, 34, 243-244.	3.4	5

#	Article	IF	Citations
199	Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases. Haematologica, 2007, 92, e96-e97.	3.5	5
200	Bortezomib inhibits T-cell function versus infective antigenic stimuli in a dose-dependent manner in vitro. Leukemia Research, 2007, 31, 1026-1027.	0.8	5
201	Molecular detection of GNNKâ^' and GNNK+ c-kit isoforms: a new tool for risk stratification in adult acute myeloid leukaemia. Leukemia, 2007, 21, 2056-2058.	7.2	5
202	Hairy Cell Leukemia. Current Treatment Options in Oncology, 2007, 8, 129-134.	3.0	5
203	Long-term propylthiouracil use and acute myeloid leukemia: A case report and review of the literature. Annals of Hematology, 2008, 87, 233-235.	1.8	5
204	Transitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemia. Leukemia Research, 2008, 32, 194-195.	0.8	5
205	JAK-2V617F mutation in RARS-t: A target for Imatinib therapy?. Leukemia Research, 2008, 32, 1636-1637.	0.8	5
206	â€˜Secondary chronic myeloid leukemiaâ€™: comparison between patients previously exposed or not to chemo- and/or radiotherapy. Leukemia and Lymphoma, 2019, 60, 3584-3586.	1.3	5
207	Comparison of ibrutinib and idelalisib plus rituximab in realâ€life relapsed/resistant chronic lymphocytic leukemia cases. European Journal of Haematology, 2021, 106, 493-499.	2.2	5
208	Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making. Blood, 2019, 134, 661-661.	1.4	5
209	Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup. Oncotarget, 2017, 8, 79188-79200.	1.8	5
210	Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools. Targeted Oncology, 2021, 16, 823-838.	3.6	5
211	First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib. Blood, 2021, 138, 1474-1474.	1.4	5
212	FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia. Anticancer Research, 2003, 23, 3419-26.	1.1	5
213	Interferon-Î± activity in a case of severe autoimmune lymphoproliferative disease. Annals of Hematology, 2001, 80, 49-52.	1.8	4
214	Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Leukemia Research, 2004, 28, 1097-1105.	0.8	4
215	Simultaneous appearance of acute myeloid leukemia in a patient with bilateral primary uveal melanoma. Melanoma Research, 2006, 16, 467-468.	1.2	4
216	Folate levels and methylation of CDKI proteins. Leukemia Research, 2007, 31, 569-570.	0.8	4

#	Article	IF	Citations
217	MDR1 modulates apoptosis in CD34+ leukemic cells. Annals of Hematology, 2008, 87, 1017-1018.	1.8	4
218	Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. Leukemia Research, 2008, 32, 192-194.	0.8	4
219	Vorinostat interferes with Wnt and NF-Î²B pathways in the M-07e cell line. Leukemia, 2009, 23, 1935-1938.	7.2	4
220	Hypercytokinemia-induced metabolic encephalopathy in a multiple myeloma patient on hemodialysis undergoing autologous stem cell transplantation: Clinical response after plasma exchange. Transplant Immunology, 2009, 21, 240-243.	1.2	4
221	correspondence: CD23 expression in plasma cell leukaemia. British Journal of Haematology, 2010, 150, 724-725.	2.5	4
222	Discordant lymphoma consisting of splenic mantle cell lymphoma and marginal zone lymphoma involving the bone marrow and peripheral blood: a case report. Journal of Medical Case Reports, 2011, 5, 476.	0.8	4
223	Autologous purified peripheral blood SCT in childhood low-risk relapsed ALL. Bone Marrow Transplantation, 2011, 46, 217-226.	2.4	4
224	Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network. Leukemia and Lymphoma, 2016, 57, 400-410.	1.3	4
225	The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study. Frontiers in Pharmacology, 2017, 8, 413.	3.5	4
226	Nextâ€generation sequencing improves BCRâ€ABL1 mutation detection in Philadelphia chromosomeâ€positive acute lymphoblastic leukaemia. British Journal of Haematology, 2021, 193, 271-279.	2.5	4
227	Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting. Leukemia Research, 2021, 104, 106552.	0.8	4
228	Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation. Frontiers in Medicine, 2021, 8, 712070.	2.6	4
229	Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. European Journal of Cancer, 2021, 157, 132-139.	2.8	4
230	Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myeloid Leukemia: Comparison with FISH and PCR Techniques. PLoS ONE, 2015, 10, e0130360.	2.5	4
231	Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study. Turkish Journal of Haematology, 2015, 32, 206-212.	0.5	4
232	The Role of Imaging in Relapse Detection During Follow up: a Fifteen-Year Single Center Experience.. Blood, 2009, 114, 5007-5007.	1.4	4
233	Myeloid neoplasms and autoimmune diseases: markers of association. Clinical and Experimental Rheumatology, 2021, , .	0.8	4
234	Quantitative Molecular Evaluation of Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia. Journal of Immunotherapy, 2004, 27, 389-393.	2.4	3

#	Article	IF	Citations
235	RAF-1 over-expression does condition survival of patients affected by aggressive mantle cell lymphoma. Leukemia Research, 2007, 31, 1595-1597.	0.8	3
236	Bortezomib is able to reduce angiogenesis in half of patients affected by idiopathic myelofibrosis: An ex vivo study. Leukemia Research, 2008, 32, 1324-1325.	0.8	3
237	Ultrasound findings guided a successful hemicolectomy in a leukemic patient with neutropenic enterocolitis. Journal of Ultrasound, 2008, 11, 97-101.	1.3	3
238	Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients. Annals of Hematology, 2011, 90, 1115-1116.	1.8	3
239	Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e13-e17.	0.4	3
240	Reduced circulating Bâ€lymphocytes and altered Bâ€cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib. Hematological Oncology, 2015, 33, 250-252.	1.7	3
241	The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients. Cancer Cell International, 2019, 19, 83.	4.1	3
242	Different types of amyloid concomitantly present in the same patients. Hematology Reports, 2019, 11, 7996.	0.8	3
243	An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. Expert Opinion on Pharmacotherapy, 2020, 21, 29-38.	1.8	3
244	Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography. Leukemia Research, 2021, 100, 106488.	0.8	3
245	Effectiveness of ibrutinib as firstâ€line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximabâ€bendamustine: Results of study on 486 cases outside clinical trials. American Journal of Hematology, 2021, 96, E269-E272.	4.1	3
246	Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. Blood, 2018, 132, 789-789.	1.4	3
247	Zinc Treatment Stimulates Thymic Regeneration after Bone Marrow Transplant. Blood, 2019, 134, 4422-4422.	1.4	3
248	A Prospective Cross-Sectional Study on the Comparison of Ultrasound Assessment vs. Palpation in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy. Journal of Clinical Medicine, 2022, 11, 3206.	2.4	3
249	Central nervous system graft-versus-host disease: consider progressive multifocal leukoencephalopathy among the differential diagnoses. Bone Marrow Transplantation, 2007, 40, 1095-1096.	2.4	2
250	MDR1 pump: More than a drug transporter. Leukemia Research, 2008, 32, 359-360.	0.8	2
251	Bortezomib and Liposomal Doxorubicin Are Highly Effective in Obtaining the Best Possible Response before Autologous Transplant for Multiple Myeloma. Acta Haematologica, 2009, 122, 39-41.	1.4	2
252	Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms. Leukemia and Lymphoma, 2011, 52, 142-144.	1.3	2

#	Article	IF	Citations
253	Imaging studies in extramedullary hematopoiesis of the spleen. Annals of Hematology, 2014, 93, 347-349.	1.8	2
254	PRDI-BF1 and PRDI-BF1Î² isoform expressions correlate with disease status in multiple myeloma patients. Hematology Reports, 2017, 9, 7201.	0.8	2
255	MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine. Pharmacogenomics Journal, 2018, 18, 444-449.	2.0	2
256	Organ Stiffness in the Work-Up of Myelofibrosis and Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Journal of Clinical Medicine, 2020, 9, 2149.	2.4	2
257	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. Journal of Clinical Medicine, 2020, 9, 3692.	2.4	2
258	Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia. European Journal of Haematology, 2020, 105, 286-291.	2.2	2
259	Longâ€term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with highâ€dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma. British Journal of Haematology, 2021, 192, 1011-1014.	2.5	2
260	Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study. Medicina (Lithuania), 2021, 57, 900.	2.0	2
261	Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. Acta OncolÃ³gica, 2021, 60, 1527-1533.	1.8	2
262	Zinc Supplementation Improves T Cell Reconstitution after Allogeneic HSCT By Stimulating Endogenous Pathways of Thymic Regeneration. Blood, 2018, 132, 3321-3321.	1.4	2
263	Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation. Blood, 2019, 134, 2919-2919.	1.4	2
264	Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party. Blood, 2019, 134, 2931-2931.	1.4	2
265	Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. Blood, 2020, 136, 43-44.	1.4	2
266	CD69, a New Potential Clinical Marker in Multiple Myeloma. Blood, 2014, 124, 2027-2027.	1.4	2
267	Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood, 2016, 128, 5697-5697.	1.4	2
268	Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy. Blood, 2016, 128, 942-942.	1.4	2
269	"Secondary Chronic Myeloid Leukemia": Comparison between Patients Previously Exposed or Not to Chemo and/or Radiotherapy. Blood, 2018, 132, 5437-5437.	1.4	2
270	Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL). Blood, 2020, 136, 16-17.	1.4	2

#	Article	IF	Citations
271	Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey. Frontiers in Oncology, 2022, 12, 828072.	2.8	2
272	Unusual morphology in a case of large granular cell leukemia. Annals of Hematology, 2001, 80, 755-757.	1.8	1
273	Oral Cyclophosphamide Therapy for Patients with Residual or Relapsed Indolent-Type Lymphoma after Initial Treatment for Aggressive Lymphomas. A Sub-group of Patients with Apparent Transformed Indolent Lymphoma. Leukemia and Lymphoma, 2002, 43, 1803-1806.	1.3	1
274	Match unrelated bone marrow transplantation in a case of high risk myelodysplastic syndrome treated with azacitidine and concomitant 1Î±-25-dihydroxyvitamin D3, as differentiating agent. Leukemia Research, 2007, 31, 1321-1323.	0.8	1
275	A therapy resistant myelodysplastic syndrome characterized by the presence of the rare reciprocal translocation t(3;12)(q26.2;p13). Leukemia Research, 2007, 31, 1599-1600.	0.8	1
276	Skin and stomach graft versus host disease after syngeneic BMT in CML: A case report. Leukemia Research, 2007, 31, 1603-1604.	0.8	1
277	Association of PIM gene translocation and TEL/AML1 rearrangement. Leukemia Research, 2007, 31, 1761-1762.	0.8	1
278	Concomitant appearance of trisomy 8 and isochromosome 17q in a Philadelphia-positive clone in a patient with chronic myeloid leukemia in chronic phase: an alarm for changing therapeutic strategy. Cancer Genetics and Cytogenetics, 2007, 177, 166-167.	1.0	1
279	Stable low IgG levels in relapsed non-Hodgkinâ€™s lymphomas. Annals of Hematology, 2007, 86, 851-853.	1.8	1
280	Concomitant translocation t(14;22)(q32;q11) in a case of chronic myeloid leukemia. Leukemia Research, 2008, 32, 188-190.	0.8	1
281	Preemptive valganciclovir for cytomegalovirus infection in hematological patients. Transplant Infectious Disease, 2008, 10, 375-376.	1.7	1
282	Pharmacogenetics and Personalized Medicine. , 2017, , 149-168.		1
283	Plasma Cell Disorders and Dialysis-Dependent Renal Failure: Safety and Efficacy of Autologous Stem Cell Transplantation. Acta Haematologica, 2018, 139, 101-103.	1.4	1
284	Favorable outcome of chronic myeloid leukemia coâ€expressing e13a2 and e14a2 transcripts, treated with nilotinib. Hematological Oncology, 2020, 38, 607-610.	1.7	1
285	Uncommon Presentation of a Common Leukemia (Chronic Lymphocytic Leukemia): Case Report. SN Comprehensive Clinical Medicine, 2020, 2, 651-652.	0.6	1
286	Thymic Reconstitution after Damage Is Influenced By Zinc Status. Biology of Blood and Marrow Transplantation, 2020, 26, S304-S305.	2.0	1
287	The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma. , 0, .		1
288	Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors. Blood, 2018, 132, 3006-3006.	1.4	1

#	Article	IF	Citations
289	Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study. Blood, 2018, 132, 4078-4078.	1.4	1
290	Role of Yttrium-90 Ibritumomab Tiuxetan (ZevalinÂ®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkinâ€™s Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen.. Blood, 2007, 110, 4498-4498.	1.4	1
291	Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter Study. Blood, 2008, 112, 3681-3681.	1.4	1
292	TNF-a Polymorphism Modulates the Outcome of Multiple Myeloma Patients Treated with Bortezomib. Blood, 2008, 112, 216-216.	1.4	1
293	Diagnostic Applications of Nuclear Medicine: Multiple Myeloma. , 2017, , 395-433.		1
294	Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation. Clinical Hematology International, 2020, 2, 129.	1.7	1
295	â€œMiroâ€•Study, a FIL multicenter phase II trial combining local radiotherapy and MRD-driven immunotherapy in early-stage follicular lymphoma.. Journal of Clinical Oncology, 2020, 38, e20073-e20073.	1.6	1
296	CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program. Blood, 2021, 138, 1262-1262.	1.4	1
297	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. Blood, 2021, 138, 2635-2635.	1.4	1
298	An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920). Blood, 2021, 138, 3746-3746.	1.4	1
299	Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). Blood, 2021, 138, 1479-1479.	1.4	1
300	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. Blood, 2020, 136, 45-46.	1.4	1
301	Joint Pain and Arthritis as First Clinical Manifestation of Systemic Amyloidosis and Multiple Myeloma: Case Report and Brief Literature Review. Hematology Reports, 2022, 14, 19-23.	0.8	1
302	A myeloablative allograft after rejection of two consecutive nonmyeloablative transplants from two different HLA identical siblings. Bone Marrow Transplantation, 2004, 33, 659-660.	2.4	0
303	Atypical APL including multiple translocations and abnormal response to micronuclei induction test. European Journal of Clinical Investigation, 2007, 37, 155-156.	3.4	0
304	Folate levels in cancer: a vitamin for a new challenge. Annals of Hematology, 2007, 86, 389-389.	1.8	0
305	Other mechanisms to explain the role of reduced folate carrier in cancer. European Journal of Haematology, 2008, 80, 365-365.	2.2	0
306	P112 Gene expression patterns in MDS with del5q before and during lenalidomide treatment. Leukemia Research, 2009, 33, S124.	0.8	0

#	Article	IF	Citations
307	THU0205â€...The temporal appearance of symptoms and signs in churg strauss syndrome: From the prodromal phase to damage. Annals of the Rheumatic Diseases, 2013, 71, 224.3-224.	0.9	0
308	No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan. Infection, 2014, 42, 1065-1066.	4.7	0
309	THU0308â€...Extensive analysis of T cell receptor gamma (TCRG) gene rearrangements reveals a similar repertoire in eosinophilic granulomatosis with polyangiitis (EGPA) and in hypereosinophilic syndrome (HES). , 2017, , .		0
310	Establishing a National Network of Laboratories Using Next Generation Amplicon Deep Sequencing for BCR-ABL1 Kinase Domain Mutation Screening in Philadelphia Chromosome-Positive Leukemias: the â€˜ NEXT-IN-CML' Study. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S310-S311.	0.4	0
311	231.â€ƒTRENDS IN LONG-TERM OUTCOMES IN EGPA: A SINGLE CENTER EXPERIENCE. Rheumatology, 2019, 58, .	1.9	0
312	004.â€ƒUSEFULNESS OF BIOMARKERS OF EOSINOPHIL ACTIVATION IN MONITORING EGPA DISEASE ACTIVITY. Rheumatology, 2019, 58, .	1.9	0
313	The Onset of Monoclonal and Oligoclonal Gammopathies Is a Good Prognostic Factor after Allogeneic Stem Cell Transplantation. Acta Haematologica, 2019, 141, 7-11.	1.4	0
314	Hematogones in patients with acute myeloid leukaemia: Prognostic value and correlation with minimal residual disease. Leukemia Research Reports, 2021, 15, 100234.	0.4	0
315	Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy. Frontiers in Oncology, 2021, 11, 638689.	2.8	0
316	Comparison of Bone Marrow Biopsy, Flow Cytometry and PCR Assays To Detect Bone Marrow Involvement in B-Cell Non-Hodgkin Lymphomas.. Blood, 2005, 106, 4670-4670.	1.4	0
317	Pharmacogenetic Study on Multiple Myeloma Patients Treated with DAV Regimen and Autologous Stem Cell Transplantation.. Blood, 2007, 110, 3468-3468.	1.4	0
318	Aggressive Non Hodgkin lymphoma'patients Treated by High Dose Chemotherapy and Immunotherapy Has a Lower Relapse Rate: Results of a Computer Science Analysis.. Blood, 2009, 114, 4772-4772.	1.4	0
319	Optimizing Follow up Schedule for Non Hodgkin Lymphoma' Patients by Multi-Objective Analysis.. Blood, 2009, 114, 3945-3945.	1.4	0
320	Association in Outcome of Advanced Multiple Myeloma with Polymorphisms of Inflammatory-Related Genes IL-1A, IL-1B, IL1RN, TNF-a and TNFRSF1B.. Blood, 2009, 114, 1723-1723.	1.4	0
321	Age-Dependent Influence of TNF-Î± Polymorphism on Progression Free Survival of ASCT In Multiple Myeloma Patients. Blood, 2010, 116, 1829-1829.	1.4	0
322	Safety and Efficacy of Pegylated Liposomal Doxorubicin In Combination with Dexamethasone and Bortezomib (VMD) or Lenalidomide (RMD) In Multiple Myeloma Refractory/Relapsed Patients. Blood, 2010, 116, 5033-5033.	1.4	0
323	Safety and Efficacy of 90Y Ibritumomab Tiuxetan (ZevalinÂ®) for Untreated FollicularNon-Hodgkin's Lymphoma (FL) Patients, An Italian Cooperative Study. Blood, 2011, 118, 100-100.	1.4	0
324	Molecular Remission After VTD or TAD As Induction for Multiple Myeloma: Results with Two Different Methods of Analysis.. Blood, 2012, 120, 2929-2929.	1.4	0

#	Article	IF	Citations
325	Non Pegylated Liposomal Doxorubicin in Combination with Dexamethasone and Lenalidomide (RMD) Is Active in Advanced MM. Blood, 2014, 124, 5742-5742.	1.4	0
326	The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy. Blood, 2016, 128, 3097-3097.	1.4	0
327	Zinc Oral Supplementation Induces a Significant Rise of TRECs and T CD4+ NaÏŠVe and Prevents the Increase of Ttv Viral Load after Stem Cell Transplantation: The Zenith Study. Blood, 2016, 128, 1230-1230.	1.4	0
328	Young CML Patients Treated Frontline with Imatinib or Second Generation TKIs: Clinical Characteristics and Outcome. Blood, 2016, 128, 3078-3078.	1.4	0
329	The hOCT1 and ABCB1 Polymorphisms Don't Condition the Efficacy and Toxicity of Nilotinib As First-Line Treatment: An Italian Multicentric Experience. Blood, 2016, 128, 3951-3951.	1.4	0
330	Radionuclide Therapy of Leukemias and Multiple Myeloma. , 2017, , 1157-1195.		0
331	Diagnostic Applications of Nuclear Medicine: Leukemias. , 2017, , 435-465.		0
332	Frontline Treatment with Dasatinib in Very Elderly Patients (> 75 Years) with Chronic Myeloid Leukemia: Is It Feasible?. Blood, 2018, 132, 5438-5438.	1.4	0
333	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Induces Genetic Instability and Can be Therapeutically Targeted. Blood, 2018, 132, 1726-1726.	1.4	0
334	Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma. Blood, 2018, 132, 4145-4145.	1.4	0
335	Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients. Blood, 2018, 132, 3021-3021.	1.4	0
336	Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement. Blood, 2019, 134, 3010-3010.	1.4	0
337	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. Blood, 2019, 134, 4153-4153.	1.4	0
338	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way. Blood, 2019, 134, 4142-4142.	1.4	0
339	COO, MYC / BCL2 Status and R-IPI Define a Group of Poor Prognosis DLBCL Patients in a Real-World Clinical Setting. Blood, 2019, 134, 1617-1617.	1.4	0
340	The Impact of Different Mobilization Strategies in the Setting of Multiple Myeloma. Blood, 2019, 134, 3254-3254.	1.4	0
341	THU0264â€…MYELOID MALIGNANCIES, SYSTEMIC AUTOIMMUNE DISEASES AND CARDIOVASCULAR RISK: AN UNDER-REPORTED ASSOCIATION?. Annals of the Rheumatic Diseases, 2020, 79, 359.2-359.	0.9	0
342	Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region. Farmeconomia E Percorsi Terapeutici, 2020, 21, .	0.1	0

#	Article	IF	Citations
343	Ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a real-life, retrospective, multicenter trial on behalf of the "RTL" (regional Tuscan lymphoma network). American Journal of Blood Research, 2021, 11, 373-383.	0.6	0
344	A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial. Blood, 2021, 138, 41-41.	1.4	0
345	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. Blood, 2020, 136, 47-48.	1.4	0
346	Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. Blood, 2020, 136, 8-9.	1.4	0